.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,866,538

« Back to Dashboard
Patent 5,866,538 protects RYZODEG 70/30, LEVEMIR, LEVEMIR FLEXPEN, LEVEMIR FLEXTOUCH, LEVEMIR INNOLET, LEVEMIR PENFILL, NOVOLOG MIX 50/50, NOVOLOG MIX 70/30, NOVOLOG MIX 70/30 FLEXPEN, NOVOLOG MIX 70/30 PENFILL, NOVOLOG, NOVOLOG FLEXPEN, NOVOLOG FLEXTOUCH, NOVOLOG INNOLET, and NOVOLOG PENFILL, and is included in five NDAs.

Protection for NOVOLOG MIX 50/50 has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-eight patent family members in twenty countries.

Summary for Patent: 5,866,538

Title: Insulin preparations containing NaCl
Abstract:Insulin preparations of superior chemical stability, comprising human insulin or an analogue or derivative thereof, glycerol and/or mannitol, and 5 to 100 mM of a halogenide are disclosed.
Inventor(s): Norup; Elsebeth (Jyllinge, DK), Langkj.ae butted.r; Liselotte (Klampenborg, DK), Havelund; Svend (Bagsvaerd, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:08/879,991
Patent Claim Types:
see list of patent claims
Formulation; Compound;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 3rd percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
RYZODEG 70/30
insulin aspart; insulin degludec
SOLUTION;SUBCUTANEOUS203313-001Sep 25, 2015RXYes5,866,538► subscribeY
Novo Nordisk Inc
LEVEMIR
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-001Jun 16, 2005RXYes5,866,538► subscribeY
Novo Nordisk Inc
LEVEMIR FLEXPEN
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-002Jun 16, 2005DISCNNo5,866,538► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,866,538

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark685/96Jun 20, 1996

International Patent Family for Patent: 5,866,538

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria208208► subscribe
Australia3253697► subscribe
Australia720484► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc